Crossmark Global Holdings Inc. Purchases 1,072 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Crossmark Global Holdings Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 16.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 7,640 shares of the biopharmaceutical company’s stock after purchasing an additional 1,072 shares during the period. Crossmark Global Holdings Inc.’s holdings in Cytokinetics were worth $403,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. J.Safra Asset Management Corp increased its holdings in Cytokinetics by 642.3% during the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 456 shares during the period. UMB Bank n.a. lifted its stake in shares of Cytokinetics by 65.6% during the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 238 shares during the last quarter. Blue Trust Inc. boosted its position in Cytokinetics by 225.9% during the third quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 680 shares in the last quarter. Values First Advisors Inc. purchased a new position in Cytokinetics in the third quarter valued at about $54,000. Finally, EntryPoint Capital LLC bought a new position in Cytokinetics in the first quarter worth about $74,000.

Cytokinetics Price Performance

Shares of CYTK stock opened at $50.22 on Friday. The firm’s 50-day moving average is $54.08 and its two-hundred day moving average is $55.25. The company has a market capitalization of $5.93 billion, a PE ratio of -9.33 and a beta of 0.78. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 12 month low of $30.68 and a 12 month high of $110.25.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $1.21 million. During the same quarter in the prior year, the firm earned ($1.35) earnings per share. Cytokinetics’s revenue was up 22.5% compared to the same quarter last year. Analysts predict that Cytokinetics, Incorporated will post -5.31 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $52.14, for a total transaction of $260,700.00. Following the sale, the chief executive officer now owns 397,456 shares of the company’s stock, valued at approximately $20,723,355.84. This represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Fady Ibraham Malik sold 7,384 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $57.01, for a total transaction of $420,961.84. Following the completion of the transaction, the executive vice president now owns 122,920 shares of the company’s stock, valued at $7,007,669.20. This trade represents a 5.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,078 shares of company stock valued at $3,261,369. Company insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CYTK. JPMorgan Chase & Co. boosted their target price on Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research note on Thursday, September 5th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a research report on Thursday, November 7th. Royal Bank of Canada assumed coverage on Cytokinetics in a research note on Friday, November 8th. They set an “outperform” rating and a $80.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research report on Friday, October 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average price target of $83.67.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.